Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals

• Status: Withdrawn
• Trial end date: 2020-07-15
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric, Randomized Comparative Study

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Abderrahmane Mami Hospital
• Collaborators: Datametrix; Eshmoun Clinical Research Centre
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• Diagnosis of COVID-19 (-)

• Works in a medical intensive care unit exposed to COVID-19 infection

• 18 years old < age < 65 years old

• Having given written consent for their participation in the study.

Exclusion Criteria:

• Diagnosis of COVID-19+

• Retinopathies,

• Hydroxychloroquine or other prophylactic treatments for VIDOC19 within one month prior to inclusion and throughout the study.

• Hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug,

• Contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance < 30 ml/min.

• Inability to be monitored during the trial period

• Pregnancy and breastfeeding

• Psoriasis